Amoytop Biotech Co. Ltd (SHA: 688278), based in Xiamen, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 biologic, peginterferon α-2b, which is indicated for the treatment of primary thrombocytosis.
As the first domestically developed long-acting peginterferon α-2b for injection in China, this drug features a 40kD polyethylene glycol structure. This unique structure enables a stable blood drug concentration over an extended period with just a once-weekly administration, significantly enhancing the convenience and patient compliance. Initially approved in China in October 2016 for the treatment of adult patients with chronic hepatitis C, the drug later expanded its indications to include chronic hepatitis B, receiving approval for this use in September 2017.- Flcube.com
